2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1481 Baseline menin inhibitor sensitivity stratifies response to menin–DOT1L versus menin–CDK9 co-inhibition in KMT2A-rearranged leukemia

Aysenur Esen, MD, Roger Luo, PhD2, Joseph Kaberlein3, Michael J. Thirman, MD4
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 University of Chicago, Chicago, Illinois, United States
3 University of Chicago, Chicago, Illinois, United States
4 University of Chicago, Chicago, Illinois, United States

Background:
Menin inhibitors have shown promising activity in KMT2A-rearranged (KMT2A-r) leukemias, but many cases have primary resistance or relapse after an initial response. Acquired resistance can be mediated by somatic mutations in MEN1, yet the mechanisms of primary resistance remain unclear. Previous research shows that menin inhibition only partially disrupts leukemic transcriptional programs, supporting the potential for biologically targeted combination therapies. Menin, DOT1L, and CDK9 participate in interconnected chromatin and transcriptional programs downstream of KMT2A fusions. We therefore asked whether baseline sensitivity to menin inhibition predicts distinct combination vulnerabilities.

Methods:
A panel of eight KMT2A-r leukemia cell lines with variable sensitivity to the menin inhibitor VTP50469 was treated with VTP50469 alone or in combination with the DOT1L inhibitor EPZ5676 or in combination with the CDK9 inhibitor AZD4573. Triple inhibition with VTP50469, EPZ5676 and AZD4573 was also tested. Cell viability was assessed by Trypan blue exclusion and cell counting. Drug interactions were quantified by ZIP synergy analysis. Post-treatment recovery after drug washout, Annexin V/PI apoptosis, and CD11b expression were evaluated. THP1 and ML2 cells were sequenced to check for the presence of known recurrent MEN1 resistance mutations.

Results:
KMT2A-r cell lines showed heterogeneous sensitivity to menin inhibition: MOLM-13, MV4;11, and KOPN-8 were highly sensitive; RS4;11, NOMO-1, and SEM were intermediately sensitive; and THP-1 and ML-2 were resistant, despite lacking recurrent MEN1 resistance mutations (S160C, M327I, G331D, and T349M), thereby providing evidence for MEN1 mutation-independent primary resistance. Menin-DOT1L co-inhibition showed synergistic activity in most KMT2A-r cell lines tested. Viability in MV4;11, MOLM-13, RS4;11, SEM, and KOPN-8 was reduced more than with either agent alone with ZIP scores of 11–54. After 14 days of treatment and subsequent washout, recovery was absent in MOLM-13 and RS4;11 and markedly impaired in MV4;11 and SEM, demonstrating that co-inhibition of menin-DOT1L can have a durable antileukemia effect. In contrast, THP-1 remained resistant to menin-DOT1L co-inhibition but sensitive to menin-CDK9 co-inhibition which was synergistic, yielding synergy scores of 12-33. Menin-CDK9 co-inhibition, compared with inhibition of either protein alone, increased both apoptosis and CD11b expression.  In ML-2 cells, the menin-CDK9 inhibitor combination reduced viability but produced an additive rather than synergistic effect. In sensitive/intermediately sensitive cell lines, menin-CDK9 co-inhibition did not further decrease viability over single agents. Although a combination of all 3 inhibitors did not reduce viability beyond the most effective dual combinations, higher CD11b expression consistent with differentiation was observed in THP-1 cells treated with the combination of all 3 drugs suggesting greater anti-leukemia activity with the triplet. 

Conclusions:
Primary resistance to menin inhibitors in KMT2A-r leukemia is heterogeneous and can occur without recurrent MEN1 gene mutations. Our findings indicate that leukemia cells responding to menin inhibitors rely on menin-dependent chromatin processes and respond well to combined menin-DOT1L inhibition. However, a subset of resistant leukemia cells to both menin inhibition and menin-DOT1L co-inhibition is vulnerable to co-inhibition of menin and CDK9, which was associated with increased apoptosis and higher CD11b expression. Overall, these results support the development of personalized menin-based combination therapies and suggest that different resistance states may require inhibition of alternative targets within the KMT2A-partner protein complex, rather than a universal combination approach.

Aysenur Esen, MD: No relevant conflicts of interest to declare.